In this issue

The arrival of the Covid-19 pandemic threw a wrench into the everyday workings of the pharma supply chain. Seemingly overnight, even the most minor of weaknesses in the system became glaringly obvious, and in some cases threatened the global supply of pharmaceutical supplies.

Although the pharma industry has been largely successful in putting out small fires as and when they arise, calls for a serious reimagining of how supply chains function only heightened as it became clear that Covid-19 wasn’t going away any time soon.

But what could a post-pandemic pharma supply chain look like? In this issue, we take a look at some of the key lessons we learn over the past year and how industry can adapt and innovate in order to prevent a similar situation from arising in the future.

Also, we go behind the scenes of the regulation process to find out exactly what it takes to get a new drug brand name approved, examine the potential of an oral Covid-19 vaccine and learn how drug manufacturers are working to improve access to rare disease treatments in India.

All this and more in this latest issue of Pharma Technology Focus.

Eloise Mclennan, editor